Your browser does not support SVG.
HOME
PIPELINE
LEADERSHIP
Management Team
Board of Directors
DISEASES
Acne vulgaris
Atopic dermatitis
Hyperhidrosis
Psoriasis
Vitiligo
NEWS
CAREERS
CONTACT
August 2020
August 2020
August 26, 2020
Dermavant Reports Positive Phase 3 Results for Tap ...
Read More
Recent Posts
Dermavant Announces First Patient Dosed in ADORING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Atopic Dermatitis
Dermavant Announces FDA Acceptance for Filing of New Drug Application (NDA) for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis
Dermavant Announces $200 Million of Financing
Dermavant Submits New Drug Application (NDA) to FDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis
Dermavant Announces Appointment of Michael Swartzburg as Chief Financial Officer
Archives
September 2021
August 2021
June 2021
May 2021
April 2021
March 2021
February 2021
January 2021
November 2020
October 2020
August 2020
June 2020
May 2020
April 2020
January 2020
December 2019
June 2019
May 2019
March 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
June 2018
April 2018
September 2017
July 2017
December 2016
November 2015
Categories
Dermavant Sciences
News
RVT-201
RVT-501
RVT-502
RVT-504
Tapinarof
